期刊文献+

甲磺酸伊马替尼耐药的人胃肠道间质瘤动物模型的建立和病理学特征分析 被引量:1

Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts
原文传递
导出
摘要 目的通过甲磺酸伊马替尼耐药细胞系建立人胃肠道间质瘤(GIST)裸鼠移植瘤模型,进一步鉴定和分析其病理学特征,为明确其耐药机制提供一个较理想的实验平台。方法甲磺酸伊马替尼耐药的GIST细胞GIST—R、GIST-PR1和GIST—PR2分别接种裸鼠观察成瘤情况。应用免疫组织化学方法检测移植瘤组织中CD117、结蛋白和myogenin等的表达情况,并进一步检测移植瘤中c-kit和血小板源生长因子受体仅(PDGFR-α)基因的突变情况。结果成功地建立了甲磺酸伊马替尼耐药的人GIST裸鼠移植瘤模型。c-kit和PDGFR—α基因突变分析结果显示,移植瘤的突变类型与接种前细胞系突变类型相一致。免疫组织化学结果显示,GIST—PR2耐药移植瘤CD117呈阳性表达,而GIST-R移植瘤CD117阴性表达。GIST—PRl耐药移植瘤呈混合细胞型,部分区域可见横纹肌肉瘤分化,横纹肌肉瘤分化区域CD117阴性表达,但是结蛋白和myogenin阳性表达。结论成功地建立了多个甲磺酸伊马替尼耐药的人GIST裸鼠移植瘤模型,同时发现其在组织病理学和免疫表型方面有着不同于耐药前GIST组织的一些特征。可以以此动物模型作为研究平台,为进一步进行甲磺酸伊马替尼耐药机制的体内外实验研究打下了基础。 Objective To establish and characterize imatinib-resistant gastrointestinal stromal tumor (GIST) xenografts. Further provided an ideal experimental platform through the imatinib-resistant GIST xenografts to investigate the mechanism of resistance to imatinib. Methods Imatinib-resistant GIST cells were injected under the skin of athymic nude mice to establish animal models of human imatinib-resistant GIST. The molecular and histopathologic features of GIST xenografts were also analysed and compared with their counterpart of cell lines. Results The xenograft tumor models had been established by subcutaneously injection of GIST cells into nude mice. Immunohistochemistry results showed CD117 expression was positive in GIST-PR2 xenograft tumor, but negative in GIST-R. In GIST-PR1, tumor areas showing rhabdomyoblastic differentiation were presented next to areas with classic GIST morphology. The rhabdomyoblastic component demonstrated consistently positivity for desmin and myogenin, whereas CD117 was completely negative. The mutation profiles of these xenograft tumors were the same as their counterpart of cell lines. Conclusions Human GIST xenografts with mutation in c-kit have been established from imatinib-resistant GIST lines. Those models will enable further studies on mechanisms of resistance, combination therapies and allow testing of novel targeted therapies.
出处 《中华病理学杂志》 CAS CSCD 北大核心 2012年第3期176-180,共5页 Chinese Journal of Pathology
关键词 胃肠肿瘤 原癌基因蛋白质c—kit 抗药性 肿瘤 肿瘤移植 动物实验 Gastrointestinal neoplasms Proto-oncogene proteins c-kit Drug resistance, neoplasm Neoplasm transplantation Animal experimentation
  • 相关文献

参考文献17

  • 1Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350) :577-580. 被引量:1
  • 2Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299 (5607) :708-710. 被引量:1
  • 3Mahadevan D, Cooke L, Riley C, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene, 2007, 26(27) :3909-3919. 被引量:1
  • 4Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol, 2007, 25(13) :1753-1759. 被引量:1
  • 5苏燕燕,杨翀,董兵,丁克峰,朱永良.人胃肠道间质瘤细胞系的建立及其永生化[J].浙江中西医结合杂志,2010,20(7):407-409. 被引量:1
  • 6郑松,陈丽荣,罗月球,王海军,程水珍,朱永良,周燕.胃肠道间质瘤中c—kit和血小板衍生生长因子受体α基因的突变及其表达研究[J].中华普通外科杂志,2007,22(8):574-578. 被引量:8
  • 7Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6) :507-519. 被引量:1
  • 8Pauwels P, Debiec-Rychter M, Stul M, et al. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment : a potential diagnostic pitfall. Histopathology, 2005, 47 (1) :41-47. 被引量:1
  • 9Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology, 2005, 128 (2) :270-279. 被引量:1
  • 10Liegl B, Hornick JL, Antonescu CR, et al. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol, 2009, 33 (2) :218-226. 被引量:1

二级参考文献8

共引文献7

同被引文献10

  • 1Hirota S, lsozaki K, Moriyama Y, et al. Gain-of-ftmction mutations of c-kit in human gastrointt+stinal stronal tunlors. Science, 1998,279 ( 5350 ) : 577-580. 被引量:1
  • 2中国胃肠道问质瘤专家组.中国胃肠道问质瘤诊断治疗共识.中华痫理学杂志,2009,38(10):697-702. 被引量:1
  • 3Wardelmann E, Merkelbach-Bruse S, Pauls K, el al. Polyclonal e;rolulion of multiple seconday KIT mutations in gash'ointestinal stromal tumors under treahnent with imatinib mesvlale. Clin Cancer Res, 2006,12 ( 6 ) : 1743-1749. 被引量:1
  • 4Heinrich MC, Corless CL, Blanke CD, el al. Molecular era'relates of imatinib resistance in gastrointeslinal stromal lunlors. J Clin Oncol, 2006,24 ( 29 ) :4764-4774. 被引量:1
  • 5Antonescu CR, Besmer P. Guo T, et al. Acquired resistance to, imadnib in gastrointeslinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res, 200.5. 11 ( 11 ) :4182-4190. 被引量:1
  • 6Al-Batrml SE, ftartnmnn JT, Hei,lel F, et al. Foeal progression m patienls with gastrointestinal stromal, tumors after inilial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer, 2007,10( 3 ) : 145-152. 被引量:1
  • 7Liegl B, Kepten 1, Le C,et al. Helerogeneily of kinase inhihitor resistance mechanisms in GIST. J Pathol, 2008,216( 1 ) :64-74. 被引量:1
  • 8Debiec-Rychter M, Cools J, Dumez tl, et al. Mechanisms of resistance to imatinih mesylate in gastrointestinal stronlai tumors and activity of the PKC412 inhihilor againsl imalinih-resistani mutants. Gastroenterology, 2005,128( 2 ) :270-279. 被引量:1
  • 9Pauwels P, Debiec-Rychter M, Slul M, el al. Changing phenolype of gaslroinlestinal stromal tumours under inmtinib mesylale treatment: a potential diagnoslie pilfall. Histopalhology, 2005,47 (1) :41-47. 被引量:1
  • 10郑松,王昊,冷建杭,童文娟,陶德友,潘月龙.Imatinib耐药的胃肠道间质瘤细胞系的建立及其生物学特征鉴定[J].中华实验外科杂志,2012,29(3):550-551. 被引量:3

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部